PDS Biotechnology Total Liabilities

PDS Biotechnology (PDSB) currently reports a total liabilities of $21B as of March 2026. That compares with $25B in the prior-year period — down 15.8% year over year. Use the charts on this page to explore PDS Biotechnology's total liabilities history and peer comparisons.

PDS Biotechnology's total liabilities decreased from $25B to $21B — a 15.8% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PDS Biotechnology reported $21B in total liabilities as of March 2026. That compares with $25B in the prior-year period — down 15.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $21B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for PDS Biotechnology, and consider following PDSB for alerts when major investors trade the stock.

PDS Biotechnology is classified in the Healthcare sector. On total liabilities, it currently shows $21B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PDSB with unrelated industries.